OPERA-01 Phase 3 study is for people with advanced and/or metastatic ER+/HER2- breast cancer that has progressed after CDK4/6 inhibitors and endocrine therapy.
Pursuing better treatments to help patients feel better, longer.
Bring your passion, join our team and make your mark.
Olema's latest news and recent events.
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)